At TRB we know the importance of taking care of our athletes’ tendons. Tendinopathy, a common injury among football players, can lead to chronic pain and even career-ending consequences. That’s why we’re excited to announce our presence at the Isokinetic Football Medicine Conference 2023 in London.
At the conference, we’ll join other experts in the field to discuss the latest advancements in football medicine and share our product’s benefits in caring for tendons and tendinopathies. Our product has been specifically designed to help alleviate the pain and discomfort experienced by players suffering from tendinopathy, while also promoting tendon healing and improving tendon function.
We encourage all sports medicine professionals to join us at the conference and contribute to the discussion on how we can improve player health worldwide. By working together, we can ensure that players receive the best possible care and support for their tendons, allowing them to perform at their best on the field. Don’t miss out on this opportunity to network with other like-minded professionals and stay up-to-date on the latest advancements in football medicine. See you there!
We are delighted to announce that we will be participating in the WCO-IOF-ESCEO Barcelona 2023, the world’s leading congress on osteoporosis, osteoarthritis and musculoskeletal diseases. This congress, organized by the International Osteoporosis Foundation (IOF) and the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO), will take place from May 4 to May 7, 2023 in Barcelona, Spain.
This is a great opportunity for us to showcase our innovative products for osteoarthritis and other musculoskeletal conditions. We will be presenting our latest research, clinical data and solutions at our booth n°28. We invite you to come and visit us and learn more about how we can help you improve your patients’ quality of life.
We look forward to meeting you at WCO-IOF-ESCEO Barcelona 2023 and sharing our passion for musculoskeletal health.
Learn more about our products for osteoarthritis and other musculoskeletal conditions on our swiss website.
We are excited to announce that TRB will be participating in the CPHI North America 2023, the premier event for the US pharma industry. Come and visit us on booth 643 from April 25-27 in Philadelphia, where you can learn more about our cutting-edge APIs, our company and our services. This is a great opportunity to find out how we can support you in reaching your objectives. We look forward to seeing you there!
Learn more about CPHI.
Find out more about TRB
At TRB Chemedica, we are committed to advancing the field of osteoarthritis treatment by researching, developing, manufacturing, and marketing various molecules, such as hyaluronic acid and diacerein, to manage osteoarthritis-induced pain.
As osteoarthritis is one of our areas of focus, we are pleased to announce our sponsorship of this year’s Osteoarthritis Research Society International (OARSI) conference in Denver, which is dedicated to advancing prevention and treatment of osteoarthritis, and thus support their mission.
The building has both a visually appealing design and several technical benefits. It is well insulated and has been optimized to reduce energy expenditure, making use of a system of microperforated plates that circulate hot or cold fluid depending on the season, resulting in lower consumption no matter the time of year.
Our dedication to environmental sustainability and energy efficiency has been a fundamental part of our company’s values long before the construction of this new building. The solar panels installed on the roof of one of our factory buildings have proven to be highly effective, generating between 15-20% of the electricity used on site, reducing our carbon footprint and demonstrating our commitment to sustainable practices.
Our new building is a testament to our company’s commitment to innovation and sustainability. Discover more about our Swissmedic’s Authorized and GMP Qualified Production Site
TRB Thailand has a long and significant history dating back to 1997, when the company first started with only three employees. Today, TRB Thailand employs over 120 people, making it a key subsidiary of the TRB Group.
To celebrate this momentous occasion, our amazing Thai team put together a fantastic party that was attended by over one hundred staff members. Speeches were given by several TRB leaders during the evening, making it a truly special event for all who attended.
The new European Medical Devices Regulation (MDR) just came into effect, with immediate application for new medical devices, generating an interesting debate. Some players welcome this major change which will align national regulations, and believe it will help to remove from the market several medical devices with limited evidence and quality control.
Others highlight that the lack of enforcement of the directives in the past rather than the gaps in regulations originated a critical situation and therefore the need for a new MDR. Still others argue that some of the new, more restrictive regulations might be detrimental to innovation. For example, the classification of most medical software has shifted to class IIa or higher, thereby putting many start-ups and medical applications under pressure.
Irrespective of any personal opinion with regard to this regulation, the more demanding reviewing processes are meant to ensure safer and more effective solutions to the patient’s health conditions.
As a non-exhaustive list of the key changes impacting our products and dossiers we can quote:
You will be able to find a more comprehensive overview on the changes in the Factsheet for healthcare professionals and health institutions, published by the European Commission.
As a Swiss pharmaceutical company, it is our duty to meet some of the highest quality standards in the world and stay one step ahead. That is why we have taken a proactive stance towards being MDR compliant. Our OSTENIL® Line, focused on rheumatology and tendinopathy, received MDR approval and new registrations for OSTENIL®, OSTENIL® Plus, OSTENIL® Mini and OSTENIL® Tendon from the 1st semester of 2022.
In a similar fashion, although we still have a few years until the deadline to switch our VISMED® ophthalmology line over to MDR, our regulatory departments are working extensively to make sure our products will be ready for conformity assessments as well as seamlessly available on the European market.
To learn more about our products, visit your local website.
World Arthritis Day, referred to as WAD, aims at increasing disease awareness and knowledge on rheumatological conditions around the world. Current estimates list more than 200 rheumatic and musculoskeletal diseases (RMD), but their burden is largely underestimated by the general population. Consequently, a large proportion of patients are either not diagnosed or wait for extended periods of time before consulting their healthcare professionals.
More than 100.000.000 people worldwide suffer from rheumatological symptoms. These symptoms directly impact the quality of life of the patients and their professional activity. The inability to work reduces individuals’ self-esteem and increases their dependence on social assistance, family and friends.
Medical education has for a long time considered RMDs as second priority conditions, which means that symptoms might go unnoticed, misdiagnosed, or mistreated if people don’t have access to rheumatologists, nurses, physical therapists, or other healthcare professionals specifically trained in the field of RMD. As a result, people living with a rheumatic or musculoskeletal disease often have to face their condition alone and are lacking information on their symptoms, diagnosis and treatment options.
World Arthritis Day is intended to raise awareness on the existence and impact of RMD worldwide. This Day is an opportunity for all communities around the world to come together and speak with one voice to bring the much-needed messages to all audiences.
Over the past 20 years, TRB Chemedica has focused its rheumatological activities on osteoarthritis, the most prevalent joint disorder especially in middle-aged and elderly people.
Every year, CPHI brings together over 100,000 pharmaceutical industry professionals from around the world in physical and online workshops for the purpose of networking and identifying business opportunities. This year’s event is expected to be one of the busiest yet with over 39,000 expected participants.
If you are planning to attend, do not miss the opportunity to visit our stand #41F52.
Please contact our team for more information or to schedule a meeting onsite.
We are proud to announce the 20th anniversary of TRB UK! Responsible for marketing our rheumatology and ophthalmology product ranges in the UK and Ireland since 2002, TRB UK is an ISO 9001 certified company, an achievement that demonstrates our commitment to patients and healthcare professionals and our dedication to quality.
You are about to leave the TRB corporate website. This link will take you to a local TRB website. Medical practices and regulations can be different from one country to another.
As a result, the medical information provided in the site which you are going to visit may not be appropriate for product use in your country.CONTINUE